Baseline characteristics for 16 enrolled patients
| Baseline characteristic . | Value . |
|---|---|
| Median age, y (range) | 66 (31-81) |
| Sex, n, male/female | 6/10 |
| Race, n | |
| White | 13 |
| Black | 0 |
| Hispanic or Latino | 1 |
| Asian | 1 |
| Other | 1 |
| Median duration of ITP, y (range) | 9 (1 to ≥ 29) |
| Comorbidities | |
| n, median | 3 |
| At least 3 comorbidities, n (%) | 8 (50) |
| History of ≥ 3 prior treatments, n (%) | 15 (94) |
| Prior treatments, n (%) | |
| Steroids | 16 (100) |
| IVIg | 15 (94) |
| Rituximab | 14 (88) |
| Splenectomy | 11 (69) |
| Anti-D | 9 (56) |
| Danazol | 8 (50) |
| Azathioprine | 6 (38) |
| Thrombopoietic agents | 5 (31) |
| Vincristine | 5 (31) |
| GMA161 | 3 (19) |
| Anti-CD40L | 2 (13) |
| Helicobacter pylori | 1 (6) |
| Median baseline platelet count, n × 109/L, (range) | 16 (2-28) |
| Baseline characteristic . | Value . |
|---|---|
| Median age, y (range) | 66 (31-81) |
| Sex, n, male/female | 6/10 |
| Race, n | |
| White | 13 |
| Black | 0 |
| Hispanic or Latino | 1 |
| Asian | 1 |
| Other | 1 |
| Median duration of ITP, y (range) | 9 (1 to ≥ 29) |
| Comorbidities | |
| n, median | 3 |
| At least 3 comorbidities, n (%) | 8 (50) |
| History of ≥ 3 prior treatments, n (%) | 15 (94) |
| Prior treatments, n (%) | |
| Steroids | 16 (100) |
| IVIg | 15 (94) |
| Rituximab | 14 (88) |
| Splenectomy | 11 (69) |
| Anti-D | 9 (56) |
| Danazol | 8 (50) |
| Azathioprine | 6 (38) |
| Thrombopoietic agents | 5 (31) |
| Vincristine | 5 (31) |
| GMA161 | 3 (19) |
| Anti-CD40L | 2 (13) |
| Helicobacter pylori | 1 (6) |
| Median baseline platelet count, n × 109/L, (range) | 16 (2-28) |
Baseline platelet count is defined as lowest count within 1 month of starting treatment. The most common comorbidities included hypertension (n = 5), dyslipidemia (n = 3), arthritis (n = 3), and diabetes (n = 3).